Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus PROFENAL.
DYLOJECT vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID